{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T20:32:02Z","timestamp":1769805122194,"version":"3.49.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004331","name":"Johnson & Johnson","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004331","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s12325-025-03416-z","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T15:13:58Z","timestamp":1763738038000},"page":"255-270","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Comparison of On-Label Treatment Persistence Through 24 Months Between Patients with Psoriatic Arthritis Initiating Guselkumab or Subcutaneous Interleukin-17A Inhibitors"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6620-0457","authenticated-orcid":false,"given":"Philip J.","family":"Mease","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jessica A.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy P.","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7957-838X","authenticated-orcid":false,"given":"Soumya D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Adamson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0060-765X","authenticated-orcid":false,"given":"Bruno","family":"Emond","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5801-6927","authenticated-orcid":false,"given":"Carmine","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel","family":"Schwartzbein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kana","family":"Yokoji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuxi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patrick","family":"Lefebvre","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominic","family":"Pilon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shikha","family":"Singla","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6514-4353","authenticated-orcid":false,"given":"Joseph F.","family":"Merola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"issue":"5","key":"3416_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24054901","volume":"24","author":"AB Azuaga","year":"2023","unstructured":"Azuaga AB, Ram\u00edrez J, Ca\u00f1ete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023;24(5):4901.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"3416_CR2","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41572-021-00293-y","volume":"7","author":"O FitzGerald","year":"2021","unstructured":"FitzGerald O, Ogdie A, Chandran V, et al. Psoriatic arthritis. Nat Rev Dis Primers. 2021;7(1):59.","journal-title":"Nat Rev Dis Primers"},{"issue":"10","key":"3416_CR3","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1002\/art.41741","volume":"73","author":"P Karmacharya","year":"2021","unstructured":"Karmacharya P, Crowson CS, Bekele D, et al. The epidemiology of psoriatic arthritis over five decades: a population-based study. Arthritis Rheumatol. 2021;73(10):1878\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"3416_CR4","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376(10):957\u201370.","journal-title":"N Engl J Med"},{"issue":"5","key":"3416_CR5","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1080\/1744666X.2018.1468252","volume":"14","author":"T Gudu","year":"2018","unstructured":"Gudu T, Gossec L. Quality of life in psoriatic arthritis. Expert Rev Clin Immunol. 2018;14(5):405\u201317.","journal-title":"Expert Rev Clin Immunol"},{"issue":"8","key":"3416_CR6","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41584-022-00798-0","volume":"18","author":"LC Coates","year":"2022","unstructured":"Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022;18(8):465\u201379.","journal-title":"Nat Rev Rheumatol"},{"issue":"6","key":"3416_CR7","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1136\/ard-2024-225531","volume":"83","author":"L Gossec","year":"2024","unstructured":"Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024;83(6):706\u201319.","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"3416_CR8","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1002\/art.40726","volume":"71","author":"J Singh","year":"2019","unstructured":"Singh J, Guyatt G, Ogdie A, et al. Special article: 2018 American College of Rheumatology\/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019;71(1):5\u201332.","journal-title":"Arthritis Rheumatol"},{"issue":"10230","key":"3416_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(20)30265-8","volume":"395","author":"A Deodhar","year":"2020","unstructured":"Deodhar A, Helliwell PS, Boehncke WH, et al. Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNF\u03b1 inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1115\u201325.","journal-title":"Lancet"},{"issue":"10230","key":"3416_CR10","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S0140-6736(20)30263-4","volume":"395","author":"PJ Mease","year":"2020","unstructured":"Mease PJ, Rahman P, Gottlieb AB, et al. Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet. 2020;395(10230):1126\u201336.","journal-title":"Lancet"},{"key":"3416_CR11","unstructured":"Tremfya. Package insert. Janssen Biotech, Inc; 2025."},{"issue":"1","key":"3416_CR12","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2020-001457","volume":"7","author":"CT Ritchlin","year":"2021","unstructured":"Ritchlin CT, Helliwell PS, Boehncke WH, et al. Guselkumab, an inhibitor of the IL-23p19 subunit, provides sustained improvement in signs and symptoms of active psoriatic arthritis: 1 year results of a phase III randomised study of patients who were biologic-na\u00efve or TNF\u03b1 inhibitor-experienced. RMD Open. 2021;7(1):e001457.","journal-title":"RMD Open"},{"issue":"2","key":"3416_CR13","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1093\/rheumatology\/keac375","volume":"62","author":"LC Coates","year":"2023","unstructured":"Coates LC, Ritchlin CT, Gossec L, et al. Guselkumab provides sustained domain-specific and comprehensive efficacy using composite indices in patients with active psoriatic arthritis. Rheumatology (Oxford). 2023;62(2):606\u201316.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"3416_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2023-003977","volume":"10","author":"LC Coates","year":"2024","unstructured":"Coates LC, Gossec L, Zimmermann M, et al. Guselkumab provides durable improvement across psoriatic arthritis disease domains: post hoc analysis of a phase 3, randomised, double-blind, placebo-controlled study. RMD Open. 2024;10(1):e003977.","journal-title":"RMD Open"},{"issue":"1","key":"3416_CR15","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s41927-024-00375-w","volume":"8","author":"LC Coates","year":"2024","unstructured":"Coates LC, Rahman P, Mease PJ, et al. Continuous improvement through differential trajectories of individual minimal disease activity criteria with guselkumab in active psoriatic arthritis: post hoc analysis of a phase 3, randomized, double-blind, placebo-controlled study. BMC Rheumatol. 2024;8(1):6.","journal-title":"BMC Rheumatol"},{"issue":"9","key":"3416_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph18094872","volume":"18","author":"E Menditto","year":"2021","unstructured":"Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872.","journal-title":"Int J Environ Res Public Health"},{"issue":"2","key":"3416_CR17","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1007\/s12325-024-03042-1","volume":"42","author":"PJ Mease","year":"2025","unstructured":"Mease PJ, Ferrante SA, Shiff NJ, et al. Comparison of on-label treatment persistence in real-world patients with psoriatic arthritis receiving guselkumab versus subcutaneous interleukin-17A inhibitors. Adv Ther. 2025;42(2):734\u201351.","journal-title":"Adv Ther"},{"key":"3416_CR18","unstructured":"Cosentyx. Package insert. Novartis Pharmaceuticals Corporation; 2024."},{"key":"3416_CR19","unstructured":"Taltz. Package insert. Eli Lilly and Company; 2024."},{"issue":"1","key":"3416_CR20","first-page":"90","volume":"29","author":"C Xu","year":"2023","unstructured":"Xu C, Ferrante SA, Fitzgerald T, et al. Inconsistencies in the days supply values reported in pharmacy claims databases for biologics with long maintenance intervals. J Manag Care Spec Pharm. 2023;29(1):90\u2013100.","journal-title":"J Manag Care Spec Pharm"},{"issue":"1","key":"3416_CR21","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2349658","volume":"35","author":"M Zhdanava","year":"2024","unstructured":"Zhdanava M, Fitzgerald T, Pilon D, et al. Comparative analysis of persistence and remission with guselkumab versus secukinumab and ixekizumab in the United States. J Dermatolog Treat. 2024;35(1):2349658.","journal-title":"J Dermatolog Treat"},{"issue":"6","key":"3416_CR22","doi-asserted-by":"publisher","first-page":"1228","DOI":"10.1080\/03610910902859574","volume":"38","author":"PC Austin","year":"2009","unstructured":"Austin PC. Using the standardized difference to compare the prevalence of a binary variable between two groups in observational research. Commun Stat - Simul Comput. 2009;38(6):1228\u201334.","journal-title":"Commun Stat - Simul Comput"},{"issue":"3","key":"3416_CR23","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1002\/acr2.11523","volume":"5","author":"CT Ritchlin","year":"2023","unstructured":"Ritchlin CT, Deodhar A, Boehncke WH, et al. Multidomain efficacy and safety of guselkumab through 1 year in patients with active psoriatic arthritis with and without prior tumor necrosis factor inhibitor experience: analysis of the phase 3, randomized, placebo-controlled DISCOVER-1 study. ACR Open Rheumatol. 2023;5(3):149\u201364.","journal-title":"ACR Open Rheumatol"},{"issue":"3","key":"3416_CR24","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/art.42010","volume":"74","author":"IB McInnes","year":"2022","unstructured":"McInnes IB, Rahman P, Gottlieb AB, et al. Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active psoriatic arthritis. Arthritis Rheumatol. 2022;74(3):475\u201385.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"3416_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1007\/s40744-023-00582-w","volume":"10","author":"PJ Mease","year":"2023","unstructured":"Mease PJ, Ogdie A, Tesser J, et al. Six-month persistence and multi-domain effectiveness of guselkumab in adults with psoriatic arthritis: real-world data from the CorEvitas psoriatic arthritis\/spondyloarthritis registry. Rheumatol Ther. 2023;10(6):1479\u2013501.","journal-title":"Rheumatol Ther"},{"issue":"2","key":"3416_CR26","first-page":"206","volume":"28","author":"MJ Murage","year":"2022","unstructured":"Murage MJ, Princic N, Park J, et al. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2022;28(2):206\u201317.","journal-title":"J Manag Care Spec Pharm"},{"issue":"12","key":"3416_CR27","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1002\/acr2.11347","volume":"3","author":"MJ Murage","year":"2021","unstructured":"Murage MJ, Princic N, Park J, et al. Real-world treatment patterns and healthcare costs in patients with psoriatic arthritis treated with ixekizumab: a retrospective study. ACR Open Rheumatol. 2021;3(12):879\u201387.","journal-title":"ACR Open Rheumatol"},{"issue":"4","key":"3416_CR28","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1007\/s13555-023-00910-6","volume":"13","author":"T Fitzgerald","year":"2023","unstructured":"Fitzgerald T, Zhdanava M, Pilon D, et al. Long-term psoriasis control with guselkumab, adalimumab, secukinumab, or ixekizumab in the USA. Dermatol Ther (Heidelb). 2023;13(4):1053\u201368.","journal-title":"Dermatol Ther (Heidelb)"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03416-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03416-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:32:07Z","timestamp":1769765527000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03416-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3416"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03416-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"25 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Philip J Mease has received research grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and UCB; consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Inmagene, Johnson & Johnson, Novartis, Pfizer, and UCB; speaker fees from AbbVie, Amgen, Eli Lilly, Janssen, Novartis, Pfizer, Spyre, Takeda, and UCB. Jessica A\u00a0Walsh received research funding from AbbVie, Merck, and Pfizer; and consulting fees from AbbVie, Eli Lilly, Johnson & Johnson, Novartis, and UCB. Timothy P Fitzgerald, Soumya D Chakravarty, and Elizabeth Adamson are employees of Johnson & Johnson, and own stock in Johnson & Johnson. Bruno Emond, Carmine Rossi, Samuel Schwartzbein, Kana Yokoji, Yuxi Wang, Patrick Lefebvre, and Dominic Pilon are employees of Analysis Group, Inc., a consulting company that has provided paid consulting services to Johnson & Johnson, which funded the development and conduct of this study. Shikha Singla received research funding from Eli Lilly, speaker fees from Johnson & Johnson, and consulting fees from AbbVie, Janssen, and UCB. Joseph F Merola is a consultant and\/or investigator for AbbVie, Amgen, Astra-Zeneca, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Dermavant, Eli Lilly, Incyte, Johnson & Johnson, Leo Pharma, Moonlake, Novartis, Pfizer, Sanofi-Regeneron, Sun Pharma, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The IQVIA PharMetrics\n                      \u00ae\n                      Plus database was used under license. In accordance with the Health Insurance Portability and Accountability Act (HIPAA), all data were de-identified; thus, Institutional Review Board review was not required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}